RVL Pharmaceuticals plc Proceeds from Common Stock Issued
RVL Pharmaceuticals plc reported Proceeds from Common Stock Issued of $23.63 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-20.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2023-03-20
- RVL Pharmaceuticals plc proceeds from issuance of common stock for the quarter ending 2022-12-31 was -$21.00K, a 100.06% decline year-over-year.
- RVL Pharmaceuticals plc proceeds from issuance of common stock for the quarter ending 2021-12-31 was $32.38M.
- RVL Pharmaceuticals plc proceeds from issuance of common stock for the quarter ending 2020-12-31 was $0.00.
- RVL Pharmaceuticals plc proceeds from issuance of common stock for the quarter ending 2020-09-30 was $30.65M.
- RVL Pharmaceuticals plc proceeds from issuance of common stock for fiscal 2022 was $23.63M, a 27.09% decline from fiscal 2021.
- RVL Pharmaceuticals plc proceeds from issuance of common stock for fiscal 2021 was $32.41M, a 48.09% decline from fiscal 2020.
- RVL Pharmaceuticals plc proceeds from issuance of common stock for fiscal 2020 was $62.44M.
- RVL Pharmaceuticals plc proceeds from issuance of common stock for fiscal 2018 was $58.08M.
| Period end | Proceeds from Issuance of Common Stock | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month | Proceeds from Issuance of Common Stock 12 month as first filed |
|---|---|---|---|---|---|---|
| 2022-12-31 | -$21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $23.63M 10-K · filed 2023-03-20 | ||||
| 2022-09-30 | $23.66M 10-Q · filed 2022-11-10 | |||||
| 2021-12-31 | $32.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $32.41M 10-K · filed 2023-03-20 | ||||
| 2021-10-12 | $26.20M 10-K · filed 2023-03-20 | |||||
| 2021-10-11 | $49.90M 10-K · filed 2023-03-20 | |||||
| 2021-09-30 | $36.00K 10-Q · filed 2021-11-15 | |||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $30.65M derived: sum of 2 quarters · filed 2022-03-30 | $30.65M derived: sum of 3 quarters · filed 2022-03-30 | $62.44M 10-K · filed 2022-03-30 | ||
| 2020-09-30 | $30.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $30.65M derived: sum of 2 quarters · filed 2021-11-15 | $62.44M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $31.79M 10-Q · filed 2021-08-16 | ||||
| 2020-03-31 | $31.79M 10-Q · filed 2021-05-13 | |||||
| 2018-12-31 | $58.08M 10-K · filed 2020-03-19 | $58.08M 10-K · filed 2019-03-28 |